Table 2.
Clinical characteristics, therapeutic management and outcomes of C.difficile infections (CDI)
| Clinical characteristics and therapeutic management of CDI | Patients (N = 388) | % (95% CI) |
|---|---|---|
| Ward of admission at onset of CDI | ||
| Intensive care | 11 | 2·9 (1·5–5·2) |
| Medical | 198 | 51·0 (45·9–56·1) |
| Haemato-oncological | 27 | 7·0 (4·7–10·1) |
| Rehabilitation | 134 | 34·5 (29·9–39·5) |
| Surgical | 18 | 4·6 (2·9–7·4) |
| Infection concomitant to CDI* | 65 | 16·8 (13·3–20·9) |
| Bloodstream infection concomitant to CDI | 36 | 9·3 (6·7–12·7) |
| Leukocyte (cells × 109/l), median (IQR) (n = 376) | 13·8 (9–20·1) | |
| Haemoglobin (g/dl), median (IQR) (n = 376) | 10·1 (8·9–11·4) | |
| Albumin (g/dl), median (IQR) (n = 243) | 2·5 (2·1–2·9) | |
| Creatinine (mg/dl), median (IQR) (n = 373) | 1·1 (0·7–1·8) | |
| Therapeutic management (n = 386) | ||
| No therapy | 15 | 3·9 (2·3–6·5) |
| Vancomycin (oral) | 261 | 67·6 (62·6–72·2) |
| Metronidazole (intravenous or oral) | 77 | 19·9 (16·2–24·4) |
| Vancomycin (oral) and metronidazole (intravenous or oral) | 33 | 8·6 (6·0–11·9) |
| Outcome of CDI | ||
| Intensive care unit admission | 7 | 1·8 (0·8–3·9) |
| Abdominal surgery | 1 | 0·3 (0·01–1·7) |
| Recurrence within 54 days | 30 | 7·7 (5·4–11·0) |
| Development of severe CDI | 73 | 18·8 (15·2–23·1) |
| 30-day all-cause mortality | 108 | 27·8 (23·4–32·6) |
CI, Confidence interval; IQR, interquartile range.
* Bloodstream = 36 (55·4%); urinary tract = 21 (32·3%); lower respiratory tract = 7 (10·7%); surgical site = 1 (1·6%).